Trade Morphosys AG - MOR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.09 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.024161% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.020283% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 20% | ||||||||
Stock exchange | Germany | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
MorphoSys AG ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 19.23 |
Open* | 19 |
1-Year Change* | -31.56% |
Day's Range* | 18.5 - 19 |
52 wk Range | 11.81-28.31 |
Average Volume (10 days) | 108.88K |
Average Volume (3 months) | 7.20M |
Market Cap | 650.41M |
P/E Ratio | -100.00K |
Shares Outstanding | 34.16M |
Revenue | 249.61M |
EPS | -25.23 |
Dividend (Yield %) | N/A |
Beta | 0.73 |
Next Earnings Date | Mar 15, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 18.87 | -0.42 | -2.18% | 19.29 | 19.29 | 18.26 |
Feb 2, 2023 | 19.23 | 0.56 | 3.00% | 18.67 | 19.71 | 18.53 |
Feb 1, 2023 | 18.43 | 0.26 | 1.43% | 18.17 | 18.73 | 18.14 |
Jan 31, 2023 | 17.96 | 0.25 | 1.41% | 17.71 | 18.27 | 17.33 |
Jan 30, 2023 | 17.96 | 0.09 | 0.50% | 17.87 | 18.22 | 17.75 |
Jan 27, 2023 | 18.06 | 0.18 | 1.01% | 17.88 | 18.27 | 17.83 |
Jan 26, 2023 | 17.96 | 0.14 | 0.79% | 17.82 | 18.18 | 17.70 |
Jan 25, 2023 | 17.73 | 0.67 | 3.93% | 17.06 | 17.79 | 16.87 |
Jan 24, 2023 | 17.00 | -0.45 | -2.58% | 17.45 | 17.69 | 16.88 |
Jan 23, 2023 | 17.47 | 0.23 | 1.33% | 17.24 | 17.73 | 16.87 |
Jan 20, 2023 | 16.94 | 0.70 | 4.31% | 16.24 | 17.23 | 16.05 |
Jan 19, 2023 | 16.30 | -0.58 | -3.44% | 16.88 | 17.11 | 15.33 |
Jan 18, 2023 | 17.04 | 0.19 | 1.13% | 16.85 | 17.27 | 16.57 |
Jan 17, 2023 | 16.97 | 0.69 | 4.24% | 16.28 | 17.01 | 16.13 |
Jan 16, 2023 | 16.47 | -0.07 | -0.42% | 16.54 | 16.82 | 16.17 |
Jan 13, 2023 | 16.42 | 1.14 | 7.46% | 15.28 | 16.80 | 15.14 |
Jan 12, 2023 | 15.12 | -0.38 | -2.45% | 15.50 | 15.68 | 14.89 |
Jan 11, 2023 | 15.06 | 0.14 | 0.94% | 14.92 | 15.13 | 14.45 |
Jan 10, 2023 | 14.63 | 0.38 | 2.67% | 14.25 | 14.94 | 14.14 |
Jan 9, 2023 | 14.36 | 0.46 | 3.31% | 13.90 | 14.47 | 13.82 |
Morphosys AG Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 49.7435 | 66.7908 | 76.4425 | 71.7553 | 327.698 | 179.612 |
Revenue | 49.7435 | 66.7908 | 76.4425 | 71.7553 | 327.698 | 179.612 |
Total Operating Expense | 109.685 | 134.398 | 136.584 | 178.803 | 301.039 | 685.818 |
Selling/General/Admin. Expenses, Total | 12.7561 | 15.7687 | 26.2302 | 55.7672 | 152.193 | 188.958 |
Research & Development | 82.1921 | 103.315 | 83.988 | 103.861 | 120.489 | 219.072 |
Depreciation / Amortization | 3.764 | 4.03 | 3.75 | 3.458 | 7.255 | 7.557 |
Interest Expense (Income) - Net Operating | 0.208 | 0.359 | -0.22 | 0.18 | -18.237 | -13.584 |
Unusual Expense (Income) | 10.141 | 9.864 | 20.224 | 9.462 | 6.795 | 231.949 |
Other Operating Expenses, Total | 0.62335 | 1.06219 | 0.81471 | 2.67494 | 13.4374 | 19.6719 |
Operating Income | -59.941 | -67.6077 | -60.1411 | -107.048 | 26.6592 | -506.207 |
Interest Income (Expense), Net Non-Operating | 0.132 | -0.768 | -0.237 | 1.354 | -35.614 | -81.632 |
Other, Net | -0.05516 | -0.41446 | -0.0987 | -0.8269 | 31.4468 | -3.21234 |
Net Income Before Taxes | -59.8642 | -68.7901 | -60.4768 | -106.52 | 22.492 | -591.051 |
Net Income After Taxes | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Net Income Before Extra. Items | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Net Income | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Income Available to Common Excl. Extra. Items | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Income Available to Common Incl. Extra. Items | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Dilution Adjustment | 0 | |||||
Diluted Net Income | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Diluted Weighted Average Shares | 26.4434 | 28.9476 | 31.3389 | 31.6112 | 33.1679 | 33.4011 |
Diluted EPS Excluding Extraordinary Items | -2.28347 | -2.41217 | -1.79241 | -3.25879 | 2.95137 | -15.4025 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | -2.0342 | -2.19068 | -1.20385 | -3.04945 | 3.20838 | -10.8879 |
Cost of Revenue, Total | 1.79663 | 3.4002 | 19.1071 | 32.1947 | ||
Gross Profit | 74.6459 | 68.3551 | 308.591 | 147.417 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 47.1896 | 38.234 | 41.2448 | 52.9435 | 41.4665 |
Revenue | 47.1896 | 38.234 | 41.2448 | 52.9435 | 41.4665 |
Cost of Revenue, Total | 5.04798 | 10.1363 | 7.48222 | 9.52819 | 7.89249 |
Gross Profit | 42.1416 | 28.0977 | 33.7625 | 43.4153 | 33.574 |
Total Operating Expense | 76.4968 | 109.175 | 122.582 | 376.565 | 111.856 |
Selling/General/Admin. Expenses, Total | 38.4237 | 40.1544 | 51.347 | 50.7098 | 36.4825 |
Research & Development | 32.3171 | 40.5068 | 62.6749 | 87.0124 | 65.048 |
Interest Expense (Income) - Net Operating | -1.1 | 1.6 | -1.7 | -3.24 | |
Unusual Expense (Income) | -0.089 | 18.604 | 0.135 | 230.949 | 0.089 |
Other Operating Expenses, Total | 1.89697 | -1.8263 | 0.94256 | 1.60571 | 2.34434 |
Operating Income | -29.3072 | -70.9412 | -81.3369 | -323.621 | -70.3899 |
Interest Income (Expense), Net Non-Operating | 7.1 | -7.7 | 4.2 | -95.782 | 3.4 |
Other, Net | -33.8928 | 113.038 | -76.8684 | 4.06089 | -55.6612 |
Net Income Before Taxes | -56.0999 | 34.3967 | -154.005 | -415.342 | -122.651 |
Net Income After Taxes | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
Net Income Before Extra. Items | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
Net Income | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
Income Available to Common Excl. Extra. Items | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
Income Available to Common Incl. Extra. Items | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
Diluted Net Income | -41.6082 | 20.8942 | -112.772 | -380.974 | -122.651 |
Diluted Weighted Average Shares | 32.7586 | 35.3712 | 34.1332 | 34.1487 | 34.1488 |
Diluted EPS Excluding Extraordinary Items | -1.27015 | 0.59071 | -3.30388 | -11.1563 | -3.59167 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | -1.27191 | 1.20559 | -3.30892 | -6.76036 | -3.58906 |
Depreciation / Amortization | 1.7 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 308.056 | 340.681 | 388.905 | 303.693 | 1206.82 | 1132.97 |
Cash and Short Term Investments | 145.074 | 164.26 | 358.964 | 272.504 | 1090.32 | 993.664 |
Cash | 73.929 | 76.589 | 45.4598 | 44.314 | 109.795 | 123.248 |
Cash & Equivalents | 1.25166 | 1.13313 | ||||
Short Term Investments | 69.8938 | 86.5382 | 313.504 | 228.19 | 980.522 | 870.416 |
Total Receivables, Net | 149.682 | 163.833 | 20.7414 | 20.3408 | 89.8356 | 85.79 |
Accounts Receivable - Trade, Net | 12.5967 | 11.2343 | 17.7329 | 15.0817 | 83.3543 | 75.911 |
Total Inventory | 0.31037 | 0.30075 | 0.24516 | 0.28821 | 9.96266 | 20.7552 |
Prepaid Expenses | 3.5 | 2.1 | 3.6 | 5.8 | 6.698 | 16.815 |
Other Current Assets, Total | 9.48947 | 10.1868 | 5.35488 | 4.75963 | 10.0035 | 15.9454 |
Total Assets | 463.6 | 415.398 | 538.764 | 496.439 | 1659.51 | 2556.25 |
Property/Plant/Equipment, Total - Net | 4.18911 | 3.52635 | 3.53071 | 47.8131 | 50.7415 | 49.5921 |
Property/Plant/Equipment, Total - Gross | 19.047 | 19.836 | 18.597 | 63.9362 | 68.4008 | 69.8613 |
Accumulated Depreciation, Total | -14.858 | -16.31 | -15.066 | -16.123 | -17.659 | -20.269 |
Goodwill, Net | 7.3648 | 7.3648 | 3.67623 | 3.67623 | 1.61923 | 335.574 |
Intangibles, Net | 60.5745 | 60.4821 | 43.6888 | 41.1221 | 69.3752 | 838.322 |
Note Receivable - Long Term | 79.5212 | 0 | ||||
Other Long Term Assets, Total | 3.89409 | 3.34429 | 2.98172 | 1.13603 | 134.373 | 199.796 |
Total Current Liabilities | 38.3019 | 47.701 | 45.9233 | 61.5579 | 200.459 | 284.538 |
Accounts Payable | 8.636 | 4.818 | 7.399 | 11.012 | 47.818 | 73.787 |
Accrued Expenses | 22.838 | 36.408 | 36.53 | 44.971 | 79.2 | 113.055 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 6.82795 | 6.47504 | 1.99429 | 3.04744 | 69.9627 | 94.0353 |
Total Liabilities | 48.1399 | 56.7272 | 50.3911 | 101.738 | 1038.19 | 2311.38 |
Total Long Term Debt | 0.21829 | 0.08779 | 0.07152 | 40.0416 | 314.724 | 322.13 |
Long Term Debt | 0.21829 | 0.08779 | 0.07152 | 0 | 272.76 | 282.785 |
Deferred Income Tax | 7.42184 | 7.81126 | 3.50723 | 0 | 5.05747 | 22.0654 |
Other Liabilities, Total | 2.19788 | 1.12709 | 0.88908 | 0.13809 | 517.951 | 1682.64 |
Total Equity | 415.46 | 358.671 | 488.373 | 394.702 | 621.322 | 244.876 |
Common Stock | 29.1598 | 29.4208 | 31.8396 | 31.958 | 32.89 | 34.2319 |
Additional Paid-In Capital | 428.361 | 438.558 | 619.908 | 628.177 | 748.979 | 833.321 |
Retained Earnings (Accumulated Deficit) | -27.5487 | -97.3751 | -152.766 | -255.78 | -157.889 | -672.349 |
Treasury Stock - Common | -14.6482 | -11.827 | -10.3988 | -8.35725 | -4.86874 | -3.08505 |
Unrealized Gain (Loss) | 0.1361 | -0.10548 | 0 | |||
Total Liabilities & Shareholders’ Equity | 463.6 | 415.398 | 538.764 | 496.439 | 1659.51 | 2556.25 |
Total Common Shares Outstanding | 28.7638 | 29.1011 | 31.5585 | 31.7322 | 32.7586 | 34.1488 |
Long Term Investments | 95.9811 | 98.999 | 196.588 | 0 | ||
Other Equity, Total | -0.21089 | -1.29572 | 2.21142 | 52.7576 | ||
Current Port. of LT Debt/Capital Leases | 2.52742 | 3.47855 | 3.66106 | |||
Capital Lease Obligations | 40.0416 | 41.9638 | 39.3458 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 1257.38 | 1255.91 | 1294.76 | 1132.97 | 1013.44 |
Cash and Short Term Investments | 1122.26 | 1095.34 | 1155.19 | 993.664 | 855.47 |
Cash | 109.586 | 297.335 | 249.767 | 123.248 | 108.873 |
Short Term Investments | 1012.67 | 798.01 | 905.426 | 870.416 | 746.597 |
Total Receivables, Net | 104.173 | 108.192 | 82.0685 | 79.227 | 80.0492 |
Accounts Receivable - Trade, Net | 101.298 | 97.1665 | 77.044 | 75.911 | 74.0944 |
Total Inventory | 13.4 | 14.5171 | 13.2692 | 20.7552 | 20.89 |
Prepaid Expenses | 17.5465 | 37.8531 | 44.2278 | 39.3234 | 57.0263 |
Total Assets | 1649.91 | 1577.41 | 2883.94 | 2556.25 | 2457.36 |
Property/Plant/Equipment, Total - Net | 49.9224 | 49.4239 | 51.9162 | 49.5921 | 48.6483 |
Goodwill, Net | 1.61923 | 1.61923 | 570.959 | 335.574 | 342.343 |
Intangibles, Net | 69.0447 | 79.0253 | 787.906 | 838.322 | 853.209 |
Long Term Investments | 125.713 | 55.3782 | 0 | 0 | |
Other Long Term Assets, Total | 146.23 | 136.061 | 178.404 | 199.796 | 199.721 |
Total Current Liabilities | 202.263 | 204.554 | 259.123 | 284.538 | 238.959 |
Payable/Accrued | 124.297 | 134.663 | 168.399 | 188.077 | 145.55 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.02894 | 3.68179 | 4.09169 | 3.66106 | 5.31028 |
Other Current Liabilities, Total | 73.9369 | 66.2085 | 86.6328 | 92.8001 | 88.0983 |
Total Liabilities | 1070.25 | 976.007 | 2286.69 | 2311.38 | 2315.62 |
Total Long Term Debt | 316.63 | 318.27 | 320.184 | 322.13 | 322.835 |
Long Term Debt | 275.193 | 277.677 | 280.218 | 282.785 | 284.218 |
Capital Lease Obligations | 41.4369 | 40.5935 | 39.9657 | 39.3458 | 38.6175 |
Deferred Income Tax | 2.32821 | 5.05747 | 23.8584 | 22.0654 | 22.5267 |
Other Liabilities, Total | 549.032 | 448.126 | 1683.53 | 1682.64 | 1731.3 |
Total Equity | 579.653 | 601.407 | 597.25 | 244.876 | 141.739 |
Common Stock | 32.89 | 32.8925 | 34.2319 | 34.2319 | 34.2319 |
Additional Paid-In Capital | 749.846 | 749.284 | 832.584 | 833.321 | 833.376 |
Retained Earnings (Accumulated Deficit) | -199.497 | -178.603 | -291.375 | -672.349 | -795 |
Treasury Stock - Common | -4.86874 | -3.78304 | -3.37201 | -3.08505 | -3.08505 |
Other Equity, Total | 1.2836 | 1.61683 | 25.1808 | 52.7576 | 72.2164 |
Total Liabilities & Shareholders’ Equity | 1649.91 | 1577.41 | 2883.94 | 2556.25 | 2457.36 |
Total Common Shares Outstanding | 32.7586 | 32.7905 | 34.141 | 34.1488 | 34.1488 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | -60.3828 | -69.8265 | -56.1721 | -103.014 | 97.8906 | -514.46 |
Cash From Operating Activities | -46.6157 | -38.4459 | -32.7813 | -81.0702 | 34.5197 | -481.445 |
Cash From Operating Activities | 3.76381 | 4.02895 | 3.75026 | 6.24516 | 8.32956 | 10.091 |
Non-Cash Items | -4.4191 | -3.29514 | 24.182 | -2.07177 | -83.4769 | 200.528 |
Cash Taxes Paid | 0.54038 | 1.86198 | 0.03384 | 0.06256 | 0.30397 | 64.6096 |
Cash Interest Paid | 0.00182 | 0 | 0.13427 | 1.01132 | 1.43149 | 4.74485 |
Changes in Working Capital | 14.4224 | 30.6468 | -4.54142 | 17.7704 | 11.7764 | -177.604 |
Cash From Investing Activities | -80.786 | 32.9325 | -177.751 | 79.4841 | -879.623 | -831.01 |
Capital Expenditures | -2.91349 | -13.1489 | -2.46532 | -3.66564 | -49.3365 | -26.1562 |
Other Investing Cash Flow Items, Total | -77.8726 | 46.0813 | -175.285 | 83.1497 | -830.286 | -804.854 |
Cash From Financing Activities | 110.403 | 8.17382 | 179.462 | 0.35324 | 907.186 | 1322.92 |
Financing Cash Flow Items | -2.78047 | -0.01553 | -15.1726 | -1.01132 | 508.655 | 1241.08 |
Issuance (Retirement) of Stock, Net | 113.19 | 0 | 193.614 | 0 | 80.5985 | 84.73 |
Issuance (Retirement) of Debt, Net | -0.00671 | 8.18935 | 1.02085 | 1.36456 | 317.933 | -2.88511 |
Foreign Exchange Effects | 0 | -0.05946 | 0.08712 | 3.39766 | 2.98531 | |
Net Change in Cash | -16.999 | 2.66047 | -31.1293 | -1.14579 | 65.4806 | 13.4536 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -41.6082 | -20.714 | -133.486 | -514.46 | -122.651 |
Cash From Operating Activities | -42.2207 | -131.585 | -323.96 | -481.445 | -143.812 |
Cash From Operating Activities | 2.31626 | 4.65405 | 7.3535 | 10.091 | 2.57174 |
Non-Cash Items | 16.223 | -79.0437 | -68.6942 | 200.528 | 36.1088 |
Cash Taxes Paid | 0.07992 | 0.08336 | 1.31085 | 64.6096 | 0.07782 |
Cash Interest Paid | 0.53635 | 2.21944 | 2.91855 | 4.74485 | 0.42117 |
Changes in Working Capital | -19.1517 | -36.4816 | -129.134 | -177.604 | -59.8415 |
Cash From Investing Activities | 33.1924 | 292.728 | -850.081 | -831.01 | 115.187 |
Capital Expenditures | -0.82796 | -12.4208 | -17.0882 | -26.1562 | -1.1706 |
Other Investing Cash Flow Items, Total | 34.0204 | 305.149 | -832.993 | -804.854 | 116.358 |
Cash From Financing Activities | 11.0258 | 27.857 | 1317 | 1322.92 | 13.7736 |
Financing Cash Flow Items | 11.8149 | 29.2795 | 1234.36 | 1241.08 | 14.5762 |
Issuance (Retirement) of Stock, Net | 0 | 0 | 84.7314 | 84.73 | |
Issuance (Retirement) of Debt, Net | -0.78905 | -1.42251 | -2.09185 | -2.88511 | -0.80261 |
Foreign Exchange Effects | -2.20631 | -1.45931 | -2.98555 | 2.98531 | 0.47603 |
Net Change in Cash | -0.20874 | 187.54 | 139.973 | 13.4536 | -14.3749 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 5.743 | 1965924 | 661108 | 2023-01-12 | LOW |
Armistice Capital LLC | Hedge Fund | 5.1648 | 1768000 | 732000 | 2023-01-10 | HIGH |
Goldman Sachs Asset Management, L.P. | Investment Advisor | 4.7869 | 1638637 | -39276 | 2023-01-18 | LOW |
T. Rowe Price International Ltd | Investment Advisor/Hedge Fund | 3.942 | 1349436 | -250322 | 2022-02-16 | MED |
RP Management, LLC | Private Equity | 3.9073 | 1337552 | 1337552 | 2021-07-29 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 3.6317 | 1243209 | 376568 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.2165 | 1101057 | -84879 | 2022-10-06 | LOW |
Adage Capital Management, L.P. | Hedge Fund | 3.2134 | 1100000 | 1100000 | 2022-12-02 | LOW |
Artisan Partners Limited Partnership | Investment Advisor | 2.9531 | 1010913 | 10045 | 2021-09-20 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.819 | 965001 | 11213 | 2022-12-31 | LOW |
Baillie Gifford & Co. | Investment Advisor | 2.4401 | 835292 | -1213122 | 2022-12-16 | LOW |
Morgan Stanley | Corporation | 1.5309 | 524062 | 524062 | 2022-11-21 | LOW |
Invesco Advisers, Inc. | Investment Advisor | 1.3857 | 474360 | 0 | 2022-12-31 | LOW |
Bank of America Corp | Corporation | 1.2942 | 443038 | 128097 | 2022-12-22 | MED |
AMG Fondsverwaltung AG | Investment Advisor | 1.2112 | 414617 | 67321 | 2022-04-30 | LOW |
Eleva Capital SAS | Investment Advisor | 1.1824 | 404760 | 404760 | 2022-10-31 | HIGH |
Lupus alpha Asset Management AG | Investment Advisor/Hedge Fund | 1.1072 | 379000 | -52000 | 2022-10-31 | MED |
Mirova | Investment Advisor | 1.0159 | 347778 | -945 | 2022-11-30 | LOW |
Candriam Luxembourg S.A. | Investment Advisor | 0.9603 | 328727 | 0 | 2022-12-31 | HIGH |
Macquarie Investment Management | Investment Advisor | 0.8764 | 300000 | 0 | 2022-12-31 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Morphosys Company profile
About MorphoSys AG
MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, MorphoSys AG revenues decreased 45% to EUR179.6M. Net loss totaled EUR514.5M vs. income of EUR97.9M. Revenues reflect USA and Canada segment decrease of 51% to EUR156.3M. Net loss reflects Impairment - Goodwill increase from EUR2.1M to EUR230.7M (expense), Other R&D increase of 80% to EUR153.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from EUR3.01 to -EUR15.40.
Equity composition
12/2008, 3-for-1 stock split.
Industry: | Biotechnology & Medical Research (NEC) |
Semmelweisstr. 7
PLANEGG
BAYERN 82152
DE
Income Statement
- Annual
- Quarterly
News

S&P 500 & DAX 40 Forecast for the Week Ahead
S&P 500 builds higher after Fed meeting, DAX 40 runs into resistance
16:30, 3 February 2023
FX Weekly Outlook: USD, GBP/USD, USD/JPY Analysis
USD, GBP/USD, USD/JPY forecasts for the week ahead.
15:56, 3 February 2023
GBP/USD drops below 1.23 as BOE comments suggest possible end of rate hikes
Despite increasing rates by 50bps at their February meeting, the messaging from the BOE suggests a dovish tilt an the possible end of rate hikes.
15:37, 2 February 2023
Gold latest: XAU/USD rallies on Fed meeting as traders eye Friday’s jobs data
Gold buyers take advantage of risk on sentiment as they eye Friday's NFP data to assess the likelihood of a soft landing
11:48, 2 February 2023
British Pound (GBP) Outlook: GBP/USD, EUR/GBP Ahead of BoE Rate Decision
Bank of England remains a dovish hiker. GBP at risk of another dovish twist
15:13, 1 February 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com